Menu
MorphoSys US

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2020

  1. 01/12/2020
    Thomas Biegi Joins MorphoSys as Head of Corporate Communications
  2. 11/11/2020
    MorphoSys Reports Nine Months and Third Quarter 2020 Results
  3. 11/11/2020
    MorphoSys and Cherry Biolabs Announce licensing of Hemibody Technology
  4. 11/11/2020
    Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
  5. 04/11/2020
    MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition
  6. 04/11/2020
    Invitation to MorphoSys' Third Quarter and First 9-Month 2020 Results Conference Call on November 12, 2020
  7. 27/10/2020
    Ad hoc: MorphoSys AG Raises its Financial Guidance for the Full Year 2020
  8. 19/10/2020
    MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)
  9. 13/10/2020
    MorphoSys AG Successfully Places EUR 325 Million Convertible Bonds
  10. 13/10/2020
    Ad hoc: MorphoSys AG Launches an Offering of approx. EUR 325 Million Convertible Bonds

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2019

  1. 24/06/2019
    Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  2. 16/05/2019
    MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
    No download available
  3. 19/02/2019
    Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
    No download available
  4. 26/01/2019
    Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
    No download available

2018

  1. 07/12/2018
    Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
    No download available
  2. 19/07/2018
    Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018
    No download available
  3. 18/04/2018
    Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
  4. 09/04/2018
    Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States
  5. 22/03/2018
    Ad hoc: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering

2017

  1. 30/11/2017
    Ad hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
    No download available

Pages

Conferences

Friday, February 26, 2021
Webcast: 10th Annual SVB Leerink Global Healthcare Conference

Dr. Jean-Paul Kress presents the Company at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021, 02:20pm EST (08:20pm CET).

Go to Webcast...

Archive

Date
Title
MP3

2021

  1. 02/26/2021

    Webcast: 10th Annual SVB Leerink Global Healthcare Conference

  2. 02/11/2021

    Guggenheim Healthcare Talks, 2021 Oncology Day

  3. 01/13/2021

    Webcast: 39th Annual J.P. Morgan Healthcare Conference

2020

  1. 12/16/2020

    Webcast: JMP Securities Hematology Summit

  2. 11/17/2020

    Stifel 2020 Virtual HC Conference

  3. 11/12/2020

    Conference Call and Webcast: Q3/9M 2020 Financial Results

  4. 09/29/2020

    Conference Call and Webcast: MorphoSys & Incyte Tafasitamab Expert Event

  5. 08/06/2020

    Conference Call and Webcast: Q2/H1 2020 Financial Results

  6. 08/03/2020

    Joint MorphoSys and Incyte Conference Call

  7. 06/18/2020

    Webcast: JMP Securities Hematology and Oncology Forum

  8. 06/10/2020

    Webcast: Goldman Sachs 41st Annual Global Healthcare Conference

  9. 06/03/2020

    Webcast: Jefferies 2020 Healthcare Conference

  10. 05/07/2020

    Conference Call and Webcast: Q1 2020 Financial Results

  11. 03/19/2020

    Conference Call and Webcast: Year End 2019

Pages

Company Update

Date
Venue
Download

2020

  1. 01/13/2021
    Company Update

Pictures

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".

 

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the Monjuvi(®) US website which is intended for US residents.

Do you wish to proceed?

Yes No